ReviewJournal of hematology & oncology2014
Signaling pathways in the development of infantile hemangioma.
Review in Journal of hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02342275 (Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review.Frontiers in pharmacology · 2024Pooled it
- Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma.BMC medical genetics · 2016Pooled it
- Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.Scientific reports · 2016Trial
- Research Progress on Angiogenesis and Involution Mechanisms of Infantile Hemangioma and Its Regulation by Active Components ofInternational journal of molecular sciences · 2026Review
- Primary intracranial infantile hemangioma presenting with hemorrhage: histopathological and immunohistochemical confirmation of a rare lesion.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Article
- Key cellular subpopulations and mechanisms of propranolol in infantile hemangioma: insights from single-cell omics.Frontiers in medicine · 2026Review
- Immune microenvironment of infantile hemangioma: cellular dynamics, molecular networks, and emerging immunomodulatory strategies.Frontiers in immunology · 2026Review
- The emerging role of non-coding RNAs in the pathogenesis of infantile hemangioma.Cancer cell international · 2025Review
- PHACE syndrome: looking backward and forward.Orphanet journal of rare diseases · 2025Review
- Transdermal delivery of timolol maleate using hydrogel microneedles for the treatment of infantile haemangiomas.Materials today. Bio · 2025Article
- Hemangioma of the abdominal wall in infancy.Journal of surgical case reports · 2025Article
- Myosin 1b Inhibits the Phenotype of HemECs to Affect the Progression of Infantile Hemangiomas.Clinical, cosmetic and investigational dermatology · 2025Article
- Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.Frontiers in oncology · 2025Review
- Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas.Drug design, development and therapy · 2025Review
- Article
- Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway.Precision clinical medicine · 2024Article
- Biological identity of orbital cavernous venous malformations.Arquivos brasileiros de oftalmologia · 2024Review
- The Role of Natural Extracts in the Management of Infantile Hemangiomas and Vascular Tumors.Pediatric health, medicine and therapeutics · 2024Review
- Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022.Heliyon · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH), which is the most common tumor in infants, is a benign vascular neoplasm resulting from the abnormal proliferation of endothelial cells and pericytes. For nearly a century, researchers have noted that IH exhibits diverse and often dramatic clinical behaviors. On the one hand, most lesions pose no threat or potential for complication and resolve spontaneously without concern in most children with IH. On the other hand, approximately 10% of IHs are destructive, disfiguring and even vision- or life-threatening. Recent studies have provided some insight into the pathogenesis of these vascular tumors, leading to a better understanding of the biological features of IH and, in particular, indicating that during hemangioma neovascularization, two main pathogenic mechanisms prevail, angiogenesis and vasculogenesis. Both mechanisms have been linked to alterations in several important cellular signaling pathways. These pathways are of interest from a therapeutic perspective because targeting them may help to reverse, delay or prevent hemangioma neovascularization. In this review, we explore some of the major pathways implicated in IH, including the VEGF/VEGFR, Notch, β-adrenergic, Tie2/angiopoietins, PI3K/AKT/mTOR, HIF-α-mediated and PDGF/PDGF-R-β pathways. We focus on the role of these pathways in the pathogenesis of IH, how they are altered and the consequences of these abnormalities. In addition, we review the latest preclinical and clinical data on the rationally designed targeted agents that are now being directed against some of these pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.